Corcept raises 2024 revenue guidance to $675-$700 million as Q3 revenue rises 48%
Corcept reported third-quarter 2024 revenue of $182.5 million, up 48% from a year earlier, and net income of $47.2 million. The company raised its full-year 2024 revenue guidance to $675 million-$700 million, from $640 million-$670 million, and said Phase 3 GRADIENT trial results support its planned new drug application for relacorilant in Cushing's syndrome.
Key points
- Q3 2024 revenue $182.5 million vs. $123.6 million in Q3 2023
- Diluted net income per share $0.41 vs. $0.28 a year earlier
- 2024 revenue guidance raised to $675 million-$700 million from $640 million-$670 million
- Relacorilant NDA submission for Cushing's syndrome expected this quarter; cash and investments $547.6 million at September 30, 2024
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:57 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 30, 2024.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.